Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Yusof Kamisah
 -- 2609 2023-02-10 04:40:52 |
2 layout
Camila Xu
 Meta information modification 2609 2023-02-10 06:27:01 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ramli, F.F.;  Hashim, S.A.S.;  Raman, B.;  Mahmod, M.;  Kamisah, Y. Trientine in Hypertrophic Cardiomyopathy. Encyclopedia. Available online: https://encyclopedia.pub/entry/41075 (accessed on 25 December 2024).
Ramli FF,  Hashim SAS,  Raman B,  Mahmod M,  Kamisah Y. Trientine in Hypertrophic Cardiomyopathy. Encyclopedia. Available at: https://encyclopedia.pub/entry/41075. Accessed December 25, 2024.
Ramli, Fitri Fareez, Syed Alhafiz Syed Hashim, Betty Raman, Masliza Mahmod, Yusof Kamisah. "Trientine in Hypertrophic Cardiomyopathy" Encyclopedia, https://encyclopedia.pub/entry/41075 (accessed December 25, 2024).
Ramli, F.F.,  Hashim, S.A.S.,  Raman, B.,  Mahmod, M., & Kamisah, Y. (2023, February 10). Trientine in Hypertrophic Cardiomyopathy. In Encyclopedia. https://encyclopedia.pub/entry/41075
Ramli, Fitri Fareez, et al. "Trientine in Hypertrophic Cardiomyopathy." Encyclopedia. Web. 10 February, 2023.
Trientine in Hypertrophic Cardiomyopathy
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ph15091145

Trientine, a copper-chelating drug used in the management of patients with Wilson’s disease, demonstrates beneficial effects in patients with hypertrophic cardiomyopathy.

cardiomyopathy diabetes hypertensive TETA

1. Introduction

Heart failure affects more than 64 million people globally [1], with its prevalence ranging from 0.12 to 6.70% [2]. It is a complication of other diseases such as diabetes mellitus [3], ischemic heart disease, or long-standing hypertension [4], or primarily due to genetic and idiopathic conditions [5]. These conditions can give rise to the development of cardiomyopathy. Myocardial hypertrophy is the most common cause of heart failure [6], characterized by enlargement of the heart [3].
Myocardial hypertrophy occurs following remodeling of the heart, triggered by various stimuli. Remodeling causes myocardial structural, molecular, and cellular changes, leading to alterations in cardiac function, size, and shape [7]. Many pathological events, such as neurohormonal activation, cardiac volume overload, and pressure overload are thought to be centrally involved in the development of cardiac hypertrophy [7]. Deficiencies in micronutrients such as copper, zinc, and selenium may also play a role in the development of heart failure [8]. Abnormality in copper homeostasis manifested by a deficiency in myocardial copper may contribute to the pathogenesis of cardiac hypertrophy [9]. Patients with ischemic heart disease tend to have a lower cardiac copper content [10], possibly due to increased myocardial copper efflux [11] and reduced activity in certain copper-dependent enzymes [10]. Animals fed a diet deficient in copper had significantly heavier hearts [12], owing to alterations in heart biochemical properties and morphology [13]. Similar observations were also noted in pressure-overloadinduced hypertrophied hearts in rats [14][15].
The exact mechanism of how copper deficiency induces cardiac hypertrophy is not well understood but may be partly attributable to dietary and hereditary etiologies. Genetic polymorphism in copper-transporting ATPase has been postulated to cause pathological cardiac changes, as observed in Menkes’ disease, an X-linked genetic defect affecting energy-dependent copper transporters [16]. Copper plays an important role in many cellular processes such as antioxidant activity and mitochondrial respiration [17]. Dietary supplementation of copper reversed cardiac hypertrophy in rats [18].
Cardiac hypertrophy and heart failure are managed pharmacologically using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers [19], β-blockers, or angiotensin receptor–neprilysin inhibitors [20][21][22]. Due to the discovery of copper-deficiency-induced cardiac hypertrophy, clinical trials have been conducted to investigate the effects of trientine, a copper chelator, on cardiac hypertrophy or hypertrophic cardiomyopathy [23][24].
Trientine, also known as triethylenetetramine (TETA) dihydrochloride (Figure 1), is an orphan drug [25]. It is an organic compound with a molecular formula of C6H18N4, which was originally approved in 1985 by the U.S. Food and Drug Administration as second-line therapy for patients with Wilson’s disease who cannot tolerate penicillamine [26][27]. Wilson’s disease is a genetic condition that arises from copper accumulation in the body, particularly the liver. This could lead to liver cirrhosis and degenerative neurological conditions which could be fatal [28]. Trientine chelates hepatic excess copper and increases urinary copper excretion, leading to hepatic improvement in the majority of patients with the disease. Other copper modulators are dimercaprol and zinc salts (acetate, sulfate, and gluconate) [27].
Pharmaceuticals 15 01145 g001
Figure 1. Molecular structure of trientine.
The role of trientine in cardiomyopathy has gained much interest, although its mechanistic action is poorly understood.

2. Role of Trientine in Cardiac Copper Regulation

Copper is required for the normal function and structure of the heart. It is involved in various cellular metabolic activities such as iron and zinc uptake, as well as oxyradical scavenging [17]. It enters cells via plasma membrane copper transporter-1 (CTR-1) and copper transporter-2 (CTR-2) [29]. Once inside the cells, the ion is delivered to its targets by various chaperones [17]. However, in excess, it may be detrimental due to the generation of reactive oxygen species (ROS). Consequently, its uptake, distribution, and elimination are tightly governed to maintain cellular homeostasis [29][30].
The serum copper level is higher in patients with cardiomyopathy compared with that of normal individuals [31]. It is postulated that increased efflux of copper from the myocardial cells leads to a high level of serum copper [32]. To confirm this, many animal model experiments using various cardiomyopathy models such as pressure-overload-induced cardiac hypertrophy [14] or diabetic cardiomyopathy [33] have been conducted. Findings from the studies confirmed the depletion of myocardial copper content measured in left ventricles [14][15][33]. The depleted content could not be replenished even in the presence of higher circulatory copper levels [11]—a phenomenon which remains elusive.
Copper exists in two valencies: Cu(I) and Cu(II). Cu(I) is mainly present intracellularly and contributes 95% of total body copper, and the remainder exists as Cu(II) in the extracellular space [34]. Its transport intracellularly is governed by various chaperones which will be discussed in the subsequent subtopics. Trientine selectively forms a complex with Cu(II), not Cu(I) [35], and serves as a copper chaperone to transport the ion to other copper-binding molecules in copper-depleted cardiomyocytes [14]. However, the mechanism is still unclear. Cu(II)-trientine enters cells as an intact complex via active transport [11]. CTR-1 expression is the major copper transporter in the heart. However, trientine does not affect myocardial CTR-1 expression [14]. Even in diabetic myocardium, it does not restore the diminished CTR-1 protein expression [34]. In cardiomyocytes transfected with CTR-1 gene silencing using siRNA, trientine-facilitated copper uptake into cardiomyocytes was unaffected, observed by increased copper accumulation in the cells. This was different from the cells that were exposed to Cu(II) chloride only, which demonstrated a decline in cellular copper content [11], confirming that the influx of copper into cells by trientine is CTR-1-independent. Studies investigating the effects of trientine on CTR-2 reported inconsistent findings (Table 1). Trientine exhibited elevated CTR-2 expression in a few studies [15][34] but no effect in another study [14]. This suggests that CTR-2 may partly contribute to copper transportation into cardiomyocytes. CTR-2 expression in the heart is determined by the cellular copper status, which is reduced in copper deficiency [36]. Therefore, trientine may upregulate CTR-2 expression indirectly due to the accumulated copper in cardiomyocytes. Another transporter that may be involved in copper transport is chloride channel CLC17 [37], and the effects of trientine on the transporter should be investigated. More studies need to be conducted to better understand the mechanisms of copper uptake by the drug.
Further studies in animals demonstrated that trientine restored myocardial copper content in cardiomyopathy models [14][34][35] (Table 1). It was previously revealed that trientine at a low dose (21.9 mg/kg, orally twice daily for 6 weeks) replenished deprived copper in the heart, but a relatively high dose (87.6 mg/kg, orally twice daily), an equivalent dose commonly used for the treatment of Wilson’s disease, failed to reload the loss of myocardial copper content in rats with pressure-overload-induced cardiac hypertrophy. Moreover, the high dose of trientine decreased copper content in the heart of normal rats, whereas the same phenomenon was not observed with the low dose [14]. The findings suggest that trientine at a relatively high dose of more than 175 mg/kg/day promotes the removal of copper from the heart. The protective effect of trientine on the myocardial copper content agreed with other animal studies that adopted a trientine dosage of approximately 100 mg/kg/day or less [15][33][34][35][38][39].
Administration of trientine exhibited protection against left ventricular hypertrophy in diabetic patients [40]. Clinical trials reported that serum copper was unaltered by trientine therapy after six [23] or twelve months [40] in patients with hypertrophic cardiomyopathy. Yet, the 24 h urinary copper level was significantly elevated in the patients, indicating increased excretion of excess copper (Table 1). However, a small significant rise in serum ceruloplasmin, the main copper-bearing protein in the blood, occurred in the patients, indicating increased cellular uptake of copper [23].
Despite the effects of trientine on myocardial copper content, it has no significant effects on plasma copper levels in rats, even though it reduces renal copper content and facilitates urinary excretion of excessive copper in the blood [14][35][39]. In other words, trientine therapy is not likely to cause systemic copper deficiency. A similar insignificant effect on plasma copper was also observed in patients with left ventricular hypertrophy who were receiving trientine. The effectiveness of the therapy was monitored by a decrease in left ventricular mass [40].
Regardless of its beneficial effects on diabetes-induced copper depletion in the heart [34][39], trientine has no significant effect on blood glucose levels in diabetic rats [25][34][39][41][42]. How it offers cardioprotection without affecting blood glucose is not understood. More mechanistic studies in experimental animals should be conducted to elucidate the mechanism.
Table 1. The effects of trientine on cardiac copper regulation in animals and related blood parameters in animals and patients with hypertrophy.
Study Type of Model/Subjects Trientine (TETA)
(Dose and Duration)		 Findings Reference
Animal STZ-induced diabetic
cardiomyopathy in rats		 20 mg/day in drinking water for 8 weeks (post-treatment) (~68 mg/kg/day) ↑ cardiac copper content
↔ CTR-1 mRNA and protein
↑ CTR-2 mRNA and protein		 [34]
Animal STZ-induced diabetic
cardiomyopathy in rats		 20 mg/day in drinking water for 8 weeks (post-treatment) (~68 mg/kg/day) ↑ cardiac copper content [38]
Animal Transverse aortic constriction-
induced cardiac hypertrophy in rats		 21.9 and 87.6 mg/kg twice daily orally for 6 weeks TETA (21.9 mg/kg/day):
↑ LV copper content
↑ urinary copper
↓ renal copper content
↔ plasma copper level
↔ CTR-1 and CTR-2 protein
TETA (87.6 mg/kg/day):
↓ LV and renal content
↑ urinary copper
↓ renal copper content
↔ plasma copper level
↔ CTR-1 and CTR-2 protein		 [14]
Animal Ascending aortic constriction-induced cardiac hypertrophy in rats 21.9 mg/kg twice daily orally for 6 weeks ↑ cardiac copper
↔ CTR-1 mRNA and protein
↑ CTR-2 mRNA and protein		 [15]
Animal STZ-induced diabetic
cardiomyopathy in rats		 (a) Intravenous infusion, 60 s once hourly in increasing doses (0.1, 1.0, 10, and 100 mg/kg)
(b) 8–11 mg/day in drinking water for 7 weeks (post-treatment)		 ↑ Copper urinary excretion
↑ Cardiac total copper		 [39]
Animal STZ-induced diabetic
cardiomyopathy in rats		 30 mg/day in drinking water for 8 weeks (post-treatment) ↑ LV total copper [33]
Human Type 2 diabetic patients with LVH (n = 15) 600 mg twice daily orally for 12 months ↔ plasma copper
↑ 24 h urinary copper		 [40]
Human Patients with hypertrophic cardiomyopathy (n = 20) 300 mg twice daily orally, increased after 1 week to 600 mg twice daily if tolerated for 6 months ↔ serum copper [23]
CTR-1, copper transporter 1; CTR-2, copper transporter 2; LV, left ventricle; LVH, left ventricular hypertrophy; STZ, streptozotocin; ↑, significant increase; ↓, significant decrease; ↔, no difference.

3. Effects of Trientine on Mitochondrial Function and Biogenesis

Copper is an essential trace element that serves as a co-factor in various enzyme activities involved in mitochondrial ATP production [8][43]. Copper is delivered to its target molecules in various organelles by chaperones [8]. Upon entering cells, copper is fetched by cytosolic copper chaperones. Cytosolic soluble cytochrome c oxidase (Cco) copper chaperones 17 (Cox17) and 11 (Cox11) are chaperones that shuttle copper to other chaperones such as mitochondrial-inner-membrane-bound Cco-assembly proteins—Sco1 and Sco2—which then deliver the copper to Cco in the mitochondria [37][44]. Cco is a copper-dependent enzyme that is actively involved in oxidative phosphorylation in the electron transport chain [44]. In cardiomyopathy, its activity is reduced [38][45].
Only two studies have investigated the effects of trientine on myocardial mitochondrial function and biogenesis. Zhang et al. [38] demonstrated that myocardial copper replenishment by trientine in the copper-deficient myocytes of diabetic rats restored normal copper trafficking between the cytoplasm and mitochondria, as evidenced by an increase in gene expressions of copper chaperones Cox17, Cox11, and Sco1 (Table 2) (Figure 2). The drug increased Cco subunits I (mt-coI) and II (mt-coII) gene expression but did not affect subunit III (mt-coIII). However, trientine did not alter the protein expression of the subunits [38]. Future studies should be conducted to investigate the effects of the drug on the mitochondrial membrane potential in cardiomyopathy since Cco and Cox17 directly affect the potential. The mitochondrial membrane potential is a crucial entity in energy storage during oxidative phosphorylation. Disturbance in the potential generation could result in mitochondrial dysfunction [46].
Pharmaceuticals 15 01145 g002
Figure 2. Sites of action of trientine in cardiac remodeling. Extracellularly, trientine reduces interstitial fibrosis by inhibiting tissue inhibitor of metalloproteinase 1/2 (TIMP1/2), leading to an increase in matrix metalloproteinases (MMPs). This, in turn, augments collagen degradation. Inhibitory effects of trientine on transforming growth factor-β1 (TGF-β1), plasminogen activator inhibitor-1 (PAI-1), and small mothers against decapentaplegic (Smad4) lead to decreases in expression of matrix proteins (collagen and fibronectin). The complex of trientine-Cu(II) is brought into cells by an unknown transporter and partly by copper transporter-2 (CTR-2). The drug increases the expression of superoxide dismutase-1 (SOD1) and -3 (SOD3) as well as copper chaperone for superoxide dismutase-1 (CCS), leading to a decrease in reactive oxygen species (ROS) formation. Trientine also elevates the expression of cytosolic soluble cytochrome c oxidase (Cco) copper chaperones 11 (Cox11) and 17 (Cox17), cytochrome c oxidase assembly protein-1/2 (Sco1/2), and peroxisome proliferator-activated receptor coactivator-1α (pgc-1α), which improves mitochondrial biogenesis and function. It also augments the expression of ATPase copper-transporting α (ATP7A) but has no effect on ATPase copper-transporting β (ATP7B) or antioxidant 1 copper chaperone (ATOX1), which are responsible for shuttling copper into trans-Golgi network or secretory vesicles. CTR-1, copper transporter 1; MT, metallothionein; nrf2, nuclear factor erythroid 2-related factor 2; tfam, mitochondrial transcription factor A; ↑, significant increase; +, stimulates; −, inhibits. Blank arrows demonstrate subsequent events; brown arrow indicates degradation, dashed blue arrow displays translocation of copper, and pink arrows indicate the sites of action of trientine.
Table 2. Effects of trientine on copper chaperones involved in cardiac mitochondrial function and biogenesis in human and animal studies.
Study Type of Model/Subjects Trientine
(Dose and Duration)		 Findings Reference
Animal STZ-induced diabetic cardiomyopathy in rats 20 mg/day in drinking water for 8 weeks (post-treatment) (~68 mg/kg/day) ↑ ATP7A
↑ Atp7a mRNA		 [34]
Animal STZ-induced diabetic cardiomyopathy in rats 20 mg/day in drinking water for 8 weeks (post-treatment) (~68 mg/kg/day) ↑ mt and cyto cox17 mRNA and protein
↑ mt and cyto cox11 protein
↑ mt Sco1 protein in LV
↑ mitochondrial Cco activity
↑ mt-coI mRNA
↑ mt-coII mRNA
↔ mt-coIII mRNA
↔ mt-coI protein
↔ mt-coII protein
↔ mt-coIII protein
↔ mt-DNA content
↔ mt-tfam mRNA
↔ mt-ssbp mRNA
↑ pgc-1α mRNA		 [38]
Human Patients with hypertrophic cardiomyopathy (n = 20) 300 mg twice daily orally, increased after 1 week to 600 mg twice daily if tolerated for 6 months ↔ PCr/ATP ratio [23]
ATP7A or Atp7a, ATPase copper-transporting α; cox11, cytosolic soluble cytochrome c oxidase (Cco) copper chaperone 11; cox17, Cco copper chaperone 17; cyto, ctytosol; LV, left ventricular; mt, mitochondria; mt-coI, mitochondrial cytosolic soluble cytochrome c oxidase (Cco) subunit I; mt-coII, mitochondrial Cco subunit II; mt-coIII, mitochondrial Cco subunit III; mt-tfam, mitochondrial transcription factor A; mt-ssbp, mitochondrial single-strand DNA-binding protein; PCr, phosphocreatine; pgc-1α, peroxisome proliferator-activated receptor coactivator-1α; Sco1, cytochrome c oxidase assembly protein-1; STZ, streptozotocin; ↑, significant increase; ↓, significant decrease; ↔, no difference.
Trientine also enhanced the expression of ATPase copper-transporting α (ATP7A) localization and its gene expression (Atp7a) in left ventricular diabetic rats [34]. ATP7A is a copper chaperone that delivers copper to ceruloplasmin in the Golgi bodies [37][44]. In terms of mitochondrial DNA synthesis, trientine did not influence mitochondrial transcription factor A (mt-tfam) or single-strand DNA-binding protein (mt-ssbp) gene expression, leading to no change in mitochondrial DNA content. However, it augmented the expression of peroxisome proliferator-activated receptor coactivator-1α (pgc-1α), a principal regulator of mitochondrial metabolism [38].
The heart has a high energy metabolism, hence it requires an energy depot for an immediate supply of ATP. Phosphocreatine represents energy storage for the rapid production of ATP. The former converts to creatine, releasing its phosphate that phosphorylates ADP, synthesizing ATP [47]. Hence, the ratio could serve as an indicator of cardiac high-energy phosphate metabolism [48]. This can be measured by using phosphorus magnetic resonance spectroscopy [49]. In patients with abnormalities in cardiac metabolism, the myocardial phosphocreatine/ATP ratio declines, and this has been shown to be prognostically relevant in models of heart failure [48]. Only one clinical trial in phase 2a has explored the effects of trientine on cardiac energetics in 20 patients with hypertrophic cardiomyopathy [23]. They found that trientine therapy at 600 mg twice daily for six months produced a non-significant 10% rise in the left ventricular phosphocreatine/ATP ratio, suggesting the potential of trientine to restore mitochondrial function and energetics in cardiomyopathy.
Collectively, trientine therapy can reverse cardiomyocyte-defective copper metabolism in cardiac hypertrophy or cardiomyopathy. This could improve mitochondrial function and bioenergetics, driving amelioration of heart structure and function. More studies on animals investigating this aspect should be conducted. Trientine may affect sirtuin-3, which is crucially involved in mitochondrial metabolism. It warrants further investigation to appreciate its role in mitochondrial function and biogenesis.

References

  1. Lippi, G.; Sanchis-Gomar, F. Global epidemiology and future trends of heart failure. AME Med. J. 2020, 5, 1–6.
  2. Savarese, G.; Lund, L.H. Global public health burden of heart failure. Card. Fail. Rev. 2017, 3, 7–11.
  3. Mohan, M.; Dihoum, A.; Mordi, I.R.; Choy, A.M.; Rena, G.; Lang, C.C. Left ventricular hypertrophy in diabetic cardiomyopathy: A target for intervention. Front. Cardiovasc. Med. 2021, 8, 746382.
  4. Maron, B.J.; Rowin, E.J.; Udelson, J.E.; Maron, M.S. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail. 2018, 6, 353–363.
  5. Chair, S.Y.; Chan, J.Y.W.; Waye, M.M.Y.; Liu, T.; Law, B.M.H.; Chien, W.T. Exploration of potential genetic biomarkers for heart failure: A systematic review. Int. J. Environ. Res. Public Health 2021, 18, 5904.
  6. Brieler, J.; Breeden, M.A.; Tucker, J. Cardiomyopathy: An overview. Am. Fam. Physician 2017, 96, 640–646.
  7. Siti, H.; Jalil, J.; Asmadi, A.Y.; Kamisah, Y. Roles of rutin in cardiac remodeling. J. Funct. Foods 2020, 64, 103606.
  8. Bomer, N.; Pavez-Giani, M.G.; Grote Beverborg, N.; Cleland, J.G.F.; van Veldhuisen, D.J.; van der Meer, P. Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism? J. Intern. Med. 2022, 291, 713–731.
  9. Medeiros, D.M. Perspectives on the role and relevance of copper in cardiac disease. Biol. Trace Elem. Res. 2017, 176, 10–19.
  10. Klevay, L.M. Cardiovascular disease from copper deficiency—A history. J. Nutr. 2000, 130, 489S–492S.
  11. Fu, C.; Lizhao, J.; Luo, Z.; Wang, T.; Grapperhaus, C.A.; Ding, X.; Kang, Y.J. Active uptake of hydrophilic copper complex Cu(ii)-TETA in primary cultures of neonatal rat cardiomyocytes. Metallomics 2019, 11, 565–575.
  12. Getz, J.; Lin, D.; Medeiros, D.M. The cardiac copper chaperone proteins Sco1 and CCS are up-regulated, but Cox 1 and Cox4 are down-regulated, by copper deficiency. Biol. Trace Elem. Res. 2011, 143, 368–377.
  13. Olivares, R.W.I.; Postma, G.C.; Schapira, A.; Iglesias, D.E.; Valdez, L.B.; Breininger, E.; Gazzaneo, P.D.; Minatel, L. Biochemical and morphological alterations in hearts of copper-deficient bovines. Biol. Trace Elem. Res. 2019, 189, 447–455.
  14. Liu, J.; Chen, C.; Liu, Y.; Sun, X.; Ding, X.; Qiu, L.; Han, P.; James Kang, Y. Trientine selectively delivers copper to the heart and suppresses pressure overload-induced cardiac hypertrophy in rats. Exp. Biol. Med. 2018, 243, 1141–1152.
  15. Liu, Y.; Xiao, Y.; Liu, J.; Feng, L.; Kang, Y.J. Copper-induced reduction in myocardial fibrosis is associated with increased matrix metalloproteins in a rat model of cardiac hypertrophy. Metallomics 2018, 10, 201–208.
  16. Nath, R. Copper deficiency and heart disease: Molecular basis, recent advances and current concepts. Int. J. Biochem. Cell. Biol. 1997, 29, 1245–1254.
  17. Cobine, P.A.; Moore, S.A.; Leary, S.C. Getting out what you put in: Copper in mitochondria and its impacts on human disease. Biochim. Biophys. Acta Mol. Cell. Res. 2021, 1868, 118867.
  18. Jiang, Y.; Reynolds, C.; Xiao, C.; Feng, W.; Zhou, Z.; Rodriguez, W.; Tyagi, S.C.; Eaton, J.W.; Saari, J.T.; Kang, Y.J. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J. Exp. Med. 2007, 204, 657–666.
  19. Koracevic, G.; Stojanovic, M.; Lovic, D.; Zdravkovic, M.; Sakac, D. Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk. J. Hum. Hypertens. 2021, 35, 564–576.
  20. Enzan, N.; Matsushima, S.; Ide, T.; Kaku, H.; Tohyama, T.; Funakoshi, K.; Higo, T.; Tsutsui, H. Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy. J. Am. Heart Assoc. 2021, 10, e019240.
  21. Alvarez, C.K.; Cronin, E.; Baker, W.L.; Kluger, J. Heart failure as a substrate and trigger for ventricular tachycardia. J. Interv. Card. Electrophysiol. 2019, 56, 229–247.
  22. Mustafa, N.H.; Jalil, J.; Zainalabidin, S.; Saleh, M.S.M.; Asmadi, A.Y.; Kamisah, Y. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Front. Pharmacol. 2022, 13, 892460.
  23. Reid, A.; Miller, C.; Farrant, J.P.; Polturi, R.; Clark, D.; Ray, S.; Cooper, G.; Schmitt, M. Copper chelation in patients with hypertrophic cardiomyopathy. Open Heart 2022, 9, e001803.
  24. McCarty, M.F.; DiNicolantonio, J.J. The protection conferred by chelation therapy in post-MI diabetics might be replicated by high-dose zinc supplementation. Med. Hypotheses 2015, 84, 451–455.
  25. Lu, J.; Gong, D.; Choong, S.Y.; Xu, H.; Chan, Y.K.; Chen, X.; Fitzpatrick, S.; Glyn-Jones, S.; Zhang, S.; Nakamura, T.; et al. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: Comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 2010, 53, 1217–1226.
  26. Cooper, G.J. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer’s disease. Drugs 2011, 71, 1281–1320.
  27. Lynch, E.N.; Campani, C.; Innocenti, T.; Dragoni, G.; Forte, P.; Galli, A. Practical insights into chronic management of hepatic Wilson’s disease. World J. Clin. Cases 2022, 10, 4334–4347.
  28. Roberts, E.A. Update on the diagnosis and management of Wilson disease. Curr. Gastroenterol. Rep. 2018, 20, 56.
  29. Mandal, T.; Kar, S.; Maji, S.; Sen, S.; Gupta, A. Structural and functional diversity among the members of ctr, the membrane copper transporter family. J. Membr. Biol. 2020, 253, 459–468.
  30. McCarty, M.F. Nutraceutical, dietary, and lifestyle options for prevention and treatment of ventricular hypertrophy and heart failure. Int. J. Mol. Sci. 2021, 22, 3321.
  31. Ford, E.S. Serum copper concentration and coronary heart disease among US adults. Am. J. Epidemiol. 2000, 151, 1182–1188.
  32. He, W.; James Kang, Y. Ischemia-induced copper loss and suppression of angiogenesis in the pathogenesis of myocardial infarction. Cardiovasc. Toxicol. 2013, 13, 1–8.
  33. Zhang, L.; Ward, M.L.; Phillips, A.R.; Zhang, S.; Kennedy, J.; Barry, B.; Cannell, M.B.; Cooper, G.J. Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats. Cardiovasc. Diabetol. 2013, 12, 123.
  34. Zhang, S.; Liu, H.; Amarsingh, G.V.; Cheung, C.C.; Hogl, S.; Narayanan, U.; Zhang, L.; McHarg, S.; Xu, J.; Gong, D.; et al. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation. Cardiovasc. Diabetol. 2014, 13, 100.
  35. Nurchi, V.M.; Crisponi, G.; Crespo-Alonso, M.; Lachowicz, J.I.; Szewczuk, Z.; Cooper, G.J. Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites. Dalton Trans. 2013, 42, 6161–6170.
  36. Bertinato, J.; Duval, S.; L’Abbé, M.R. Copper transporter 2 content is lower in liver and heart of copper-deficient rats. Int. J. Mol. Sci. 2010, 11, 4741–4749.
  37. Lutsenko, S. Copper trafficking to the secretory pathway. Metallomics 2016, 8, 840–852.
  38. Zhang, S.; Liu, H.; Amarsingh, G.V.; Cheung, C.C.H.; Wu, D.; Narayanan, U.; Zhang, L.; Cooper, G.J.S. Restoration of myocellular copper-trafficking proteins and mitochondrial copper enzymes repairs cardiac function in rats with diabetes-evoked heart failure. Metallomics 2020, 12, 259–272.
  39. Cooper, G.J.; Phillips, A.R.; Choong, S.Y.; Leonard, B.L.; Crossman, D.J.; Brunton, D.H.; Saafi, L.; Dissanayake, A.M.; Cowan, B.R.; Young, A.A.; et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004, 53, 2501–2508.
  40. Cooper, G.J.; Young, A.A.; Gamble, G.D.; Occleshaw, C.J.; Dissanayake, A.M.; Cowan, B.R.; Brunton, D.H.; Baker, J.R.; Phillips, A.R.; Frampton, C.M.; et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: A randomised placebo-controlled study. Diabetologia 2009, 52, 715–722.
  41. Baynes, J.W.; Murray, D.B. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp. Diabetes Res. 2009, 2009, 696378.
  42. Gong, D.; Lu, J.; Chen, X.; Choong, S.Y.; Zhang, S.; Chan, Y.-K.; Glyn-Jones, S.; Gamble, G.D.; Phillips, A.R.; Cooper, G.J. Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats. Mol. Pharmacol. 2006, 70, 2045–2051.
  43. Fukai, T.; Ushio-Fukai, M.; Kaplan, J.H. Copper transporters and copper chaperones: Roles in cardiovascular physiology and disease. Am. J. Physiol. Cell. Physiol. 2018, 315, C186–C201.
  44. Chen, J.; Jiang, Y.; Shi, H.; Peng, Y.; Fan, X.; Li, C. The molecular mechanisms of copper metabolism and its roles in human diseases. Pflügers Arch. 2020, 472, 1415–1429.
  45. Vogt, S.; Ruppert, V.; Pankuweit, S.; Paletta, J.P.J.; Rhiel, A.; Weber, P.; Irqsusi, M.; Cybulski, P.; Ramzan, R. Myocardial insufficiency is related to reduced subunit 4 content of cytochrome c oxidase. J. Cardiothorac. Surg. 2018, 13, 95.
  46. Zorova, L.D.; Popkov, V.A.; Plotnikov, E.Y.; Silachev, D.N.; Pevzner, I.B.; Jankauskas, S.S.; Babenko, V.A.; Zorov, S.D.; Balakireva, A.V.; Juhaszova, M.; et al. Mitochondrial membrane potential. Anal. Biochem. 2018, 552, 50–59.
  47. Balestrino, M. Role of creatine in the heart: Health and disease. Nutrients 2021, 13, 1215.
  48. Wibowo, P.G.; Charman, S.J.; Okwose, N.C.; Velicki, L.; Popovic, D.; Hollingsworth, K.G.; Macgowan, G.A.; Jakovljevic, D.G. Association between cardiac high-energy phosphate metabolism and whole body metabolism in healthy female adults. Physiol. Res. 2021, 70, 393–399.
  49. Burrage, M.K.; Hundertmark, M.; Valkovič, L.; Watson, W.D.; Rayner, J.; Sabharwal, N.; Ferreira, V.M.; Neubauer, S.; Miller, J.J.; Rider, O.J.; et al. Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction. Circulation 2021, 144, 1664–1678.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Fitri Fareez Ramli
,
Syed Alhafiz Syed Hashim
,
Betty Raman
,
Masliza Mahmod
,
Yusof Kamisah
View Times: 597
Entry Collection: Hypertension and Cardiovascular Diseases
Revisions: 2 times (View History)
Update Date: 10 Feb 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback